|
Novo Nordisk’s CagriSema Falls Short of Investor Expectations Despite Promising Weight-Loss Results
|
Written by: J. Smith |
Hits: 838
|
|
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
|
Written by: J. Smith |
Hits: 911
|
|
Possible Link Between Semaglutide and Vision Loss Raises Questions
|
Written by: J. Smith |
Hits: 1057
|
|
Dexcom Launches First Generative AI Platform in Glucose Biosensing
|
Written by: J. Smith |
Hits: 936
|
|
Eli Lilly and Novo Nordisk Ramp Up GLP-1 Manufacturing Capacity
|
Written by: J. Smith |
Hits: 1740
|
|
Novo Nordisk to Slash US Insulin Prices in 2026
|
Written by: J. Smith |
Hits: 1861
|
|
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
|
Written by: J. Smith |
Hits: 953
|
|
Exploring CGM Data
|
Written by: J. Smith |
Hits: 884
|
|
Dexcom and Oura: A Strategic Partnership to Revolutionize Metabolic Health Tracking
|
Written by: J. Smith |
Hits: 1125
|
|
Lilly's Three-Year SURMOUNT-1 Data Demonstrates Tirzepatide’s Role in Diabetes Prevention
|
Written by: J. Smith |
Hits: 886
|
